Neurotrophins in the lower urinary tract: Becoming of age

Current Neuropharmacology

Volumn 9, Issue 4, 2011, Pages 553-558

  Frias, Bárbara ^a,b   Lopes, Tiago ^c   Pinto, Rui ^a   Cruz, Francisco ^a,b,c   Cruz, Célia Duarte ^a,b  

^a Institute of Histology and Embryology   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

^c HOSPITAL DE SÃO JOÃO   (Portugal)

Author keywords

BDNF; Bladder; LUT; NGF; Trk receptors

Indexed keywords

ANANDAMIDE; BRAIN DERIVED NEUROTROPHIC FACTOR; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; CANNABINOID 1 RECEPTOR; NERVE GROWTH FACTOR; NERVE GROWTH FACTOR RECEPTOR; VANILLOID RECEPTOR 1;

ARTICLE; BINDING AFFINITY; BLADDER DYSFUNCTION; BLADDER NECK STENOSIS; HUMAN; LOWER URINARY TRACT SYMPTOM; NONHUMAN; OVERACTIVE BLADDER; PATHOGENESIS; PATHOPHYSIOLOGY; RECEPTOR BINDING; URETHRA; URINE;

EID: 82955220550     PISSN: 1570159X     EISSN: 18756190     Source Type: Journal    
DOI: 10.2174/157015911798376253     Document Type: Article

References (96)

1. Fowler, C. J., Griffiths, D., de Groat, W. C. The neural control of micturition. Nat. Rev. Neurosci., 2008, 9, 453-466.
2. Andersson, K. E., Wein, A. J. Pharmacology of the lower urinary tract: basis for current and future treatments of urinary incontinence. Pharmacol. Rev., 2004, 56, 581-631.
3. Yoshimura, N., Chancellor, M. B. Current and future pharmacological treatment for overactive bladder. J. Urol., 2002, 168, 1897 913.
4. de Groat, W. C., Yoshimura, N. Pharmacology of the lower urinary tract. Annu. Rev. Pharmacol. Toxicol., 2001, 41, 691-721.
5. Merighi, A., Carmignoto, G., Goboo, S., Lossi, L., Salio, C., Vergnano, A. M., Zonta, M. Neurotrophins in spinal cord nociceptive pathways. Prog. Brain. Res., 2004, 146, 291-321.
6. Pezet, S., McMahon, S. B. Neurotrophins: mediators and modulators of pain. Annu. Rev. Neurosci., 2006, 29, 507-538.
7. Allen, S. J., Dawbarn, D. Clinical relevance of the neurotrophins and their receptors. Clin. Sci., 2006, 110, 175-191.
8. Levi-Montalcini, R. The nerve growth factor 35 years later. Science, 1987, 237, 1154-1162.
9. Kaplan, D. R., Miller, F. D. Neurotrophin signal transduction in the nervous system. Curr. Opin. Neurobiol., 2000, 10, 381-391.
10. Chao, M. V. Neurotrophins and their receptors: a convergence point for many signalling pathways. Nat. Rev. Neurosci., 2003, 4, 299-309.
11. Lu, B., Pang, P., Woo, N. H. The ying and yang of neurotrophin action. Nat. Rev. Neurosci., 2005, 6, 603-614.
12. Huang, E. J., Reichardt, L. F. Trk receptors: roles in neuronal signal transduction. Annu. Rev. Biochem., 2003, 72, 609-642.
13. Hefti, F. F., Rosenthal, A., Walicke, P. A., Wyatt, S., Vergara, G., Shelton, D. L., Davies, A. M. Novel class of pain drugs based on antagonism of NGF. Trends in Pharmacol. Sci., 2006, 27, 85-91.
14. Obata, K., Yamanaka, H., Dai, Y., Tchabana, T., Fukuoka, T., Tokunaga, A., Yoshikawa, H., Noguchi, K. Differential activation of extracellular signal-regulated protein kinase in primary afferent neurons regulates brain-derived neurotrophic factor expression after peripheral inflammation and nerve injury. J. Neurosci., 2003, 23, 4117-41126.
15. Levi-Montalcini, R. Nerve growth factor. Science, 1975, 187, 113.
16. Watson, A. Y., Anderson, J. K., Siminoski, K. Cellular and subcellular colocalization of nerve growth factor and epidermal growth factor in mouse submandibular glands. Anat. Rec., 1985, 213, 365 376.
17. Nam, J.W., Chung, J. W., Kho, H. S., Chung, S. C., Kim, Y. K. (Nerve growth factor concentration in human saliva. Oral Dis., 2007, 13, 187-192.
18. Montaño, J. A., Pérez-Piñera, P., García-Suárez, O., Cobo, J., Vega, J. A. Development and neuronal dependence of cutaneous sensory nerve formations: Lessons from neurotrophins. Microsc. Res. Tech., 2010, 73, 513-529.
19. Birder, L. A., Wolf-Johnston, A., Griffiths, D., Resnick, N. M. Role of urothelial nerve growth factor in human bladder function. Neurourol. Urodyn., 2007, 26, 405-409.
20. Pincelli, C., Marconi, A. Autocrine nerve growth factor in human keratinocytes. J. Dermatol. Sci., 2000, 22, 71-79.
21. Stanzel, R. D., Lourenssen, S., Blennerhassett, M. G. (Inflammation causes expression of NGF in epithelial cells of the rat colon. Exp. Neurol., 2008, 211, 203-213.
22. Bennett, D. H., Koltzenburg, M., Priestley, J. V., Shelton, D. L., McMahon, S. B. Endogenous nerve growth factor regulates the sensitivity of nociceptors in the adult rat. Eur. J. Neurosci., 1998, 10, 1282-1291.
23. Dmitrieva, N., Shelton, D., Rice, A. S., McMahon, S. B. The role of nerve growth factor in a model of visceral inflammation. Neurosci., 1997, 78, 449-459.
24. Jaggar, S, I., Scott, H. F., Rice, A, C. Inflammation of the rat urinary bladder is associated with referred thermal hyperalgesia which is nerve growth factor dependent. Br. J. Anaesth., 1999, 83(3), 442-448.
25. Lowe, E. M., Anand, P., Terenghi, G., Williams-Chestnut, R. E., Sinicropi, D. V., Osborne, J. L. Increased nerve growth factor levels in the urinary bladder of women with idiopathic sensory urgency and interstitial cystitis. Br. J. Urol., 1997, 79, 572-577.
26. McMahon, S. B., Dmitrieva, N., Koltzenburg, M. Visceral Pain. Br. J. Anesth., 1995, 75, 132-144.
27. Woolf, C. J., Safieh-Garabedian, B., Ma, Q. P., Crilly, P., Winter, J. Nerve growth factor contributes to the generation of inflammatory sensory hypersensitivity. Neuroscience, 1994, 62, 327-331.
28. Steers, W. D., Tuttle, J. B. Mechanisms of Disease: the role of nerve growth factor in the pathophysiology of bladder disorders. Nat. Clin. Pract. Urol., 2005, 3, 101-110.
29. McMahon, S. B., Bennett, D. L., Bevan, S. Inflammatory mediators and modulators. In Textbook of Pain, ed. SB McMahon, M Koltzenburg, pp. 49-72. London: Elsevier., 2006.
30. Bonnington, J. K., McNaughton, P. A. Signalling pathways involved in the sensitization of mouse nociceptive neurons by nerve growth factor. J. Physiol., 2003, 551, 433-446.
31. Huang, J., Zhang, X., McNaughton, P. A. Modulation of temperature sensitive TRP channels. Semin. Cell. Dev. Biol., 2006a, 17, 638-645.
32. Huang, J., Zhang, X., McNaughton, P. A. Inflammatory pain: the cellular basis of heat hyperalgesia. Curr. Neuropharmacol., 2006b, 4, 197-206.
33. Zhang, X., Huang, J., McNaughton, P. A.) NGF rapidly increases membrane expression of TRPV1 heat-gated ion channels. EMBO J., 2005, 24, 4211-4223.
34. Ahluwalia, J., Urban, L., Capogna, M., Bevan, S., Nagy, I. Cannabinoid 1 receptors are expressed in nociceptive primary sensory neurons. Neuroscience, 2000, 100, 685-688.
35. Ahluwalia, J., Urban, L., Bevan, S., Capogna, M., Nagy, I. Cannabinoid 1 receptors are expressed by nerve growth factor and glial cell-derived neurotrophic factor-responsive primary sensory neurones. Neuroscience, 2002, 110, 747-753.
36. Ahluwalia, J., Urban, L., Bevan, S., Nagy, I. Anandamide regulates neuropeptide release from capsaicin-sensitive primary sensory neurons by activating both the cannabinoid 1 receptor and the vanilloid receptor 1 in vitro. Eur. J. Neurosci., 2003, 17, 2611-2618.
37. Devane, W.A., Hanus, L., Breuer, A., Pertwee, R.G., Stevenson, L.A., Griffin, G., Gibson, D., Mandelbaum, A., Etinger, A., Mechoulam, R Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science, 1992, 258, 1946-1949.
38. Dinis, P., Charrua, A., Avelino, A., Yaqoob, M., Bevan, S., Nagy, I., Cruz, F. Anandamide-evoked activation of vanilloid receptor 1 contributes to the development of bladder hyperreflexia and nociceptive transmission to spinal dorsal horn neurons in cystitis. J. Neurosci., 2004, 24, 11253-11263.
39. De Petrocellis, L., Harrison, S., Bisogno, T., Tognetto, M., Brandi, I., Smith, G.D., Creminon, C., Davis, J.B., Geppetti, P., Di Marzo, V. The vanilloid receptor (VR1)-mediated effects of anandamide are potently enhanced by the cAMP-dependent protein kinase. J. Neurochem., 2001, 77, 1660-1663.
40. Tognetto, M., Amadesi, S., Harrison, S., Creminon, C., Trevisani, M., Carreras, M., Matera, M., Geppetti, P., Bianchi, A. Anandamide excites central terminals of dorsal root ganglion neurons via vanilloid receptor-1 activation. J. Neurosci., 2001, 21, 1104 1109.
41. Evans, R.M., Scott, R.H., Ross, R.A. Chronic exposure of sensory neurones to increased levels of nerve growth factor modulates CB1/TRPV1 receptor crosstalk. Br. J. Pharmacol., 2007, 152, 404 413.
42. Farquhar-Smith, W.P., Rice, A.S. Administration of endocannabinoids prevents a referred hyperalgesia associated with inflammation of the urinary bladder. Anesthesiology, 2001, 94, 507-513.
43. Farquhar-Smith, W.P., Jaggar, S.I., Rice, A.S. Attenuation of nerve growth factor-induced visceral hyperalgesia via cannabinoid CB(1) and CB(2)-like receptors. Pain, 2002, 97, 11-21.
44. Farquhar-Smith, W.P., Rice, A.S. A novel neuroimmune mechanism in cannabinoid-mediated attenuation of nerve growth factorinduced hyperalgesia. Anesthesiology, 2003, 99, 1391-1401.
45. Steers, W.D., Kolbeck, S., Creedon, D., Tuttle, J.B. Nerve growth factor in the urinary bladder of the adult regulates neuronal form and function. J. Clin. Invest., 1991, 88, 1709-1715.
46. Clemow, D.B., McCarty, R., Steers, W.D., Tuttle, J.B. Efferent and afferent neuronal hypertrophy associated with micturition pathways in spontaneously hypertensive rats. Neurourol. Urodyn., 1997, 16, 293-303.
47. Gabella, G., Berggren, T., Uvelius, B. Hypertrophy and reversal of hypertrophy in rat pelvic ganglion neurons. J. Neurocytol., 1992, 21, 649-662.
48. Steers, W.D., Creedon, D.J., Tuttle, J.B. Immunity to nerve growth factor prevents afferent plasticity following urinary bladder hypertrophy. J. Urol., 1996, 155, 379-385.
49. Abrams, P. New words for old: lower urinary tract symptoms for "prostatism". Br. Med. J., 1994, 308, 929-930.
50. Abrams, P., Cardozo, L., Fall, M., Griffiths, D., Rosier, P., Ulmsten, U., van Kerrebroeck, P., Victor, A., Wein, A. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol. Urodyn., 2002, 21, 167-178.
51. Irwin, D. E., Milsom, I., Hunskaar, S., Reilly, K., Kopp, Z., Herschorn, S., Coyne, K., Kelleher, C., Hampel, C., Artibani, W., Abrams, P. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur. Urol., 2006, 50, 1306 1314.
52. Hashim, H., Abrams, P. Overactive bladder: an update. Curr. Opinion Urol., 2007, 17, 231-236.
53. rading, A. F. Pathophysiology of the Overactive Bladder. In: Corcos, J., Schick, E., editors. Textbook of the neurogenic bladder. Adults and Children. Martin Dunitz: London, UK, 2004; pp. 131 141.
54. Chapple, C. R., Artibani, W., Cardozo, L. D., Castro-Diaz, D., Craggs, M., Haab, F., Khullar, V., Versi, E. The role urinary urgency and its measurement in the overactive bladder symptom syndrome: current concepts and future prospects. Br. J. Urol., 2005, 95, 335-340.
55. Kuo, H. C. Recent investigations of urinary nerve growth factor as a biomarker for overactive bladder syndrome. Korean J. Urol., 2009, 50, 831-835.
56. Kim, J. C., Park, E. Y., Seo, S. I., Park, Y. H., Hwang, T. K. Nerve growth factor and prostaglandins in the urine of female patients with overactive bladder. J. Urol., 2006, 175, 1773-1776.
57. Liu, H. T., Kuo, H.C. Urinary nerve growth factor level could be a potential biomarker for diagnosis of patients with overactive bladder. J. Urol., 2008, 179, 2270-2274.
58. Yokoyama, T., Kumon, H., Nagai, A. Correlation of urinary nerve growth factor level with pathogenesis of overactive bladder. Neurourol. Urodyn., 2008, 27, 417-420.
59. Liu, H. T., Chancellor, M. B., Kuo, H. C. Urinary nerve growth factor levels are elevated in patients with detrusor overactivity and decreased in responders to detrusor botulinum toxin-A injection. Eur. Urol., 2009, 56, 700-707.
60. Pinto, R., Lopes, T., Frias, B., Silva, A., Silva, J. A., Silva, C. M., Cruz, C., Cruz, F., Dinis, P. Trigonal Injection of Botulinum Toxin A in Patients with Refractory Bladder Pain Syndrome/Interstitial Cystitis. Eur. Urol., 2010, 58, 360-365.
61. Okragly, A.J., Niles, A.L., Saban, R., Schmidt, D., Hoffman, R.L., Warner, T.F., Moon, T.D., Uehling, D., Haak-Frendscho, M. Elevated tryptase, nerve growth factor, neurotrophin-3 and glial cell line-derived neurotrophic factor levels in the urine of interstitial cystitis and bladder cancer patients. J. Urol., 1999, 161, 438-441.
62. Giannantoni, A., Di Stasi, S.M., Nardicchi, V., Zucchi, A., Macchioni, L., Bini, V., Goracci, G., Porena, M. Botulinum-A toxin injections into the detrusor muscle decrease nerve growth factor bladder tissue levels in patients with neurogenic detrusor overactivity. J. Urol., 2006, 175, 2341-2344.
63. Qiao, Li-Ya, Vizzard, M. A. Cystitis-Induced upregulation of tyrosine kinase (TrkA, TrkB) receptor expression and phosphorylation in rat micturition pathways. J. Comp. Neurol., 2002a, 454, 200 211.
64. Qiao, L., Vizzard, M. A. Up-regulation of tyrosine kinase (Trka, Trkb) receptor expression and phosphorylation in lumbosacral dorsal root ganglia after chronic spinal cord (T8-T10) injury. J. Comp. Neurol., 2002b, 449, 217-230.
65. Vizzard, M. A. Changes in Urinary Bladder Neurotrophic Factor mRNA and NGF Protein Following Urinary Bladder Dysfunction. Exp. Neurol., 2000, 161, 273-284.
66. Chuang, Y. C., Fraser, M. O., Yu, Y., Chancellor, M. B., de Groat, W. C., Yoshimura, N. The role of bladder afferent pathways in bladder hyperactivity induced by the intravesical administration of nerve growth factor. J. Urol., 2001, 165, 975-979.
67. Lamb, K., Gebhart, G. F., Bielefeldt, K. Increased nerve growth factor expression triggers bladder overactivity. J. Pain, 2004, 5, 150-156.
68. Yoshimura, N., Bennett, N. E., Hayashi, Y., Ogawa, T., Nishizawa, O., Chancellor, M. B., de Groat, W. C., Seki, S. Bladder overactivity and hyperexcitability of bladder afferent neurons after intrathecal delivery of nerve growth factor in rats. J. Neurosci., 2006, 26, 10847-10855.
69. Zvara, P., Vizzard, M. A. Exogenous overexpression of nerve growth factor in the urinary bladder produces bladder overactivity and altered micturition circuitry in the lumbosacral spinal cord. BMC, 2007, Physiol., 7, 9.
70. Hu, V. Y., Zvara, P., Dattilio, A., Redman, T. L., Allen, S. J., Dawbarn, D., Stroemer, P., Vizzard, M. A. Decrease in Bladder Overactivity with REN1820 in rats with cyclophosphamide induced cystitis. J. Urol,. 2005, 173, 1016-1021.
71. Seki, S., Sasaki, K., Fraser, M. O., Igawa, Y., Nishizawa, O., Chancellor, M. B., de Groat, W. C., Yoshimura, N. Immunoneutralization of nerve growth factor in lumbosacral spinal cord reduces bladder hyperreflexia in spinal cord injured rats. J. Urol., 2002, 168, 2269-2274.
72. Seki, S., Sasaki, K., Igawa, Y., Nishizawa, O., Chancellor, M. B., de Groat, W. C., Yoshimura, N. Suppression of detrusor-sphincter dyssynergia by immunoneutralization of nerve growth factor in lumbosacral spinal cord in spinal cord injured rats. J. Urol., 2004, 171, 478-482.
73. Dmitrieva, N., McMahon, S.B. Sensitisation of visceral afferents by nerve growth factor in the adult rat. Pain, 1996, 66, 87-97.
74. Jaggar, S.I., Scott, H.C., Rice, A.S. Inflammation of the rat urinary bladder is associated with a referred thermal hyperalgesia which is nerve growth factor dependent. Br. J. Anaesth., 1999, 83, 442-448.
75. Guerios, S.D., Wang, Z.Y., Boldon, K., Bushman, W., Bjorling, D.E. Blockade of NGF and trk receptors inhibits increased peripheral mechanical sensitivity accompanying cystitis in rats. Am. J. Physiol. Regul. Integr. Comp. Physiol., 2008, 295, R111-R122.
76. Pezet, S., Malcangio, M., McMahon, S. B. BDNF: a neuromodulator in nociceptive pathways? Brain Res. Rev., 2002a, 40, 240-249.
77. Kerr, B. J., Bradbury, E. J., Bennett, D. H., Trivedi, P. M., Dassan, P., French, J., Shelton, D. B., McMahon, S. B., Thompson, S. N. Brain-derived neurotrophic factor modulates nociceptive sensory inputs and NMDA-evoked responses in the rat spinal cord. J. Neurosci., 1999, 19, 5138-5148.
78. Merighi, A., Salio, C., Ghirri, A., Lossi, L., Ferrini, F., Betelli, C., Bardoni, R. BDNF as a pain modulator. Prog. Neurobiol., 2008, 85, 297-317.
79. Michael, G. J., Averill, S., Nitkunan, A., Rattray, M., Bennett, D. L., Yan, Q., Priestley, J. V. Nerve growth factor treatment increases brain-derived neurotrophic factor selectively in TrkA-expressing dorsal root ganglion cells and in their central terminations within the spinal cord. J. Neurosci., 1997, 17, 8476-8490.
80. Hellard, D., Brosenitsch, T., Fritzsch, B., Katz, D.M. Cranial sensory neuron development in the absence of brain-derived neurotrophic factor in BDNF/Bax double null mice. Dev. Biol., 2004, 275, 34-43.
81. Sedy, J., Szeder, V., Walro, J.M., Ren, Z.G., Nanka, O. Pacinian corpuscle development involves multiple trk signaling pathways. Dev. Dyn., 2004, 231, 551.
82. Uchida, N., Kanazawa, M., Suzuki, Y., Takeda, M. Expression of BDNF and trkB in mouse taste buds after denervation and in circumvallate papillae during development. Arch. Histol. Cytol., 2003, 66, 17-25.
83. Carroll, P., Lewin, G. R., Koltzenburg, M., Toyka, K. V., Thoenen, H. A role for BDNF in mechanosensation. Nat. Neurosci., 1998, 1, 42-46.
84. Mcilwrath, S. L., Hu, J., Anirudhan, G., Shin, J. B., Lewin, G. R. The sensory mechanotransduction ion channel ASIC2 (acid sensitive ion channel 2) is regulated by neurotrophin availability. Neuroscience, 2005, 131, 499-511.
85. Obata, K., Noguchi, K. BDNF in sensory neurons and chronic pain. Neurosci. Res., 2006, 55, 1-10.
86. Zhou, X. F., Rush, R. A. Endogenous brain-derived neurotrophic factor is anterogradely transported in primary sensory neurons. Neuroscience, 1996, 74, 945-951.
87. Lommatzsch M., Braun, A., Mannsfeldt, A., Botchkarev, V. A., Botchkareva, N. V., Paus, R., Fischer, A., Lewin, G. R., Renz, H. (Abundant production of brain-derived neurotrophic factor by adult visceral epithelia. Implications for paracrine and target-derived neurotrophic functions. Am. J. Pathol., 1999, 155, 1183-1193.
88. Pinto, R., Frias, B., Allen, S., Dawbarn, D., McMahon, S. B., Cruz, F., Cruz, C. D. Sequestration of brain derived nerve factor by intravenous delivery of TrkB-Ig2 reduces bladder overactivity and noxious input in animals with chronic cystitis. Neuroscience, 2010a, 166, 907-916.
89. Lu, Y., Christian, K., Lu, B. BDNF: a key regulator for protein synthesis-dependent LTP and long-term memory? Neurobiol. Learn. Mem., 2008, 89, 312-323.
90. Zhao, J., Seereeram, A., Nassar, M. A., Levato, A., Pezet, S., Hathaway, G., Morenilla-Palao, C., Stirling, C., Fitzgerald, M., McMahon, S. B., Rios, M., Wood, J. N. Nociceptor-derived brainderived neurotrophic factor regulates acute and inflammatory but not neuropathic pain. Mol. Cell. Neurosci., 2006, 31, 539-548.
91. Shu, X. Q., Llinas, A., Mendell, L. M. Effects of TrkB and TrkC receptor agonists on thermal nociception: a behavioral and electrophysiological study. Pain, 1999, 80, 463-470.
92. Thompson, S. W. N., Bennett, D. L., Kerr, B. J., Bradbury, E. J., McMahon, S. B. Brain-derived neurotrophic factor is an endogenous modulator of nociceptive responses in the spinal cord. Proc. Natl. Acad. Sci., 1999, 96, 7714-7718.
93. Pezet, S., Malcangio, M., Lever, I. J., Perkinton, M. S., Thompson, S. W., Williams, R. J., McMahon, S. B. Noxious stimulation induces Trk receptor and downstream ERK phosphorylation in spinal dorsal horn. Mol. Cell Neurosci., 2002b, 21, 684-695.
94. Slack, S. E., Thompson, S. N. Brain-derived neurotrophic factor induces NMDA receptor I phosphorylation in rat spinal cord. Neuroreport, 2002, 13, 1967-1970.
95. Slack, S. E., Pezet, S., McMahon, S. B., Thompson, S. N., Malcangio, M. Brain-derived neurotrophic factor induces NMDA receptor subunit one phosphorylation via ERK and PKC in the rat spinal cord. Eur. J. Neurosci., 2004, 20, 1769-1778.
96. Groth, R., Aanonsen, L. Spinal brain-derived neurotrophic factor (BDNF) produces hyperalgesia in normal mice while antisense directed against either BDNF or TrkB, prevent inflammationinduced hyperalgesia. Pain, 2002, 100, 171-181.